NCT00154219

Efficacy and Safety Study of Lumiracoxib in Patients With Primary Hip Osteoarthritis

A 13-week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel Group Trial of Lumiracoxib (COX189) 100 mg o.d. in Patients With Primary Hip Osteoarthritis Using Celecoxib (200 mg o.d.) as a Positive Control

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 1,200 (planned)
• Sponsor: Novartis · Industry
• Sex: All
• Age: 40 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy, tolerability, and safety of the investigational drug, lumiracoxib as compared to celecoxib and placebo in subjects with hip osteoarthritis. Both lumiracoxib and celecoxib belong to the same class of drug (COX-2 selective nonsteroidal anti-inflammatory drugs \[NSAIDs\]).

Conditions

• Osteoarthritis, Hip

Interventions

Type	Name	Description
DRUG	Lumiracoxib (drug)

Timeline

• Start date: 2004-11-01
• Primary completion: 2006-10-01
• First posted: 2005-09-12
• Last updated: 2012-05-21

Locations

5 sites across 5 countries: United States, Canada, Germany, Italy, United Kingdom